Abstract
The neuregulin 1 (NRG1) receptor ErbB4 is involved in the development of cortical inhibitory GABAergic circuits and NRG1-ErbB4 signaling has been implicated in schizophrenia (SCZ). A magnetic resonance spectroscopy (1H-MRS) study has demonstrated that a single-nucleotide polymorphism in ERBB4, rs7598440, influences human cortical GABA concentrations. Other work has highlighted the significant impact of this genetic variant on expression of ERBB4 in the hippocampus and dorsolateral prefrontal cortex in human post mortem tissue. Our aim was to examine the association of rs7598440 with cerebrospinal fluid (CSF) GABA levels in healthy volunteers (n=155). We detected a significant dose-dependent association of the rs7598440 genotype with CSF GABA levels (G-allele standardized β=−0.23; 95% CIs: −0.39 to −0.07; P=0.0066). GABA concentrations were highest in A homozygous, intermediate in heterozygous, and lowest in G homozygous subjects. When excluding subjects on psychotropic medication (three subjects using antidepressants), the results did not change (G-allele standardized β=−0.23; 95% CIs: −0.40 to −0.07; P=0.0051). The explained variance in CSF GABA by rs7598440 in our model is 5.2% (P=0.004). The directionality of our findings agrees with the aforementioned 1H-MRS and gene expression studies. Our observation therefore strengthens the evidence that the A-allele of rs7598440 in ERBB4 is associated with increased GABA concentrations in the human central nervous system (CNS). To our knowledge, our finding constitutes the first confirmation that CSF can be used to study genotype–phenotype correlations of GABA levels in the CNS. Such quantitative genetic analyses may be extrapolated to other CSF constituents relevant to SCZ in future studies.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G et al (1998). International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50: 291–313.
Bohlen P, Huot S, Palfreyman MG (1979). The relationship between GABA concentrations in brain and cerebrospinal fluid. Brain Res 167: 297–305.
Chen YJ, Zhang M, Yin DM, Wen L, Ting A, Wang P et al (2011). ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. Proc Natl Acad Sci USA 107: 21818–21823.
Epperson CN, O’Malley S, Czarkowski KA, Gueorguieva R, Jatlow P, Sanacora G et al (2005). Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry 57: 44–48.
Fazzari P, Paternain AV, Valiente M, Pla R, Lujan R, Lloyd K et al (2010). Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 464: 1376–1380.
Grove J, Palfreyman MG, Schechter PJ (1983). Cerebrospinal fluid GABA as an index of brain GABA activity. Clin Neuropharmacol 6: 223–229.
Grove J, Schechter PJ, Hanke NF, de Smet Y, Agid Y, Tell G et al (1982). Concentration gradients of free and total gamma-aminobutyric acid and homocarnosine in human CSF: comparison of suboccipital and lumbar sampling. J Neurochem 39: 1618–1622.
Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH et al (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12: 824–828.
Hare TA (1981). Alterations of central GABAergic activity in neurologic and psychiatric disorders: evaluation through measurements of GABA and GAD activity in cerebrospinal fluid. Mol Cell Biochem 39: 297–304.
Hull J, Campino S, Rowlands K, Chan MS, Copley RR, Taylor MS et al (2007). Identification of common genetic variation that modulates alternative splicing. PLoS Genet 3: e99.
Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, Kamiya A, Brandon NJ, Sawa A (2009). Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci 32: 485–495.
Kwon OB, Paredes D, Gonzalez CM, Neddens J, Hernandez L, Vullhorst D et al (2008). Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc Natl Acad Sci USA 105: 15587–15592.
Law AJ, Kleinman JE, Weinberger DR, Weickert CS (2007). Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 16: 129–141.
Li D, Collier DA, He L (2006). Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15: 1995–2002.
Manyam BV, Hare TA (1983). Cerebrospinal fluid GABA measurements: basic and clinical considerations. Clin Neuropharmacol 6: 25–36.
Marenco S, Geramita M, van der Veen JW, Barnett AS, Kolachana B, Shen J et al (2011). Genetic association of ErbB4 and human cortical GABA levels in vivo. J Neurosci 31: 11628–11632.
Mei L, Xiong WC (2008). Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9: 437–452.
Neddens J, Fish KN, Tricoire L, Vullhorst D, Shamir A, Chung W et al (2011). Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia. Biol Psychiatry 70: 636–645.
Sauna ZE, Kimchi-Sarfaty C (2011). Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12: 683–691.
Spielberger C (1989). State-Trait Anxiety Inventory:v A Comprehensive Bibliography. Consulting Psychologists Press: Palo Alto.
Visser WF, Verhoeven-Duif NM, Ophoff R, Bakker S, Klomp LW, Berger R et al (2011). A sensitive and simple ultra-high-performance-liquid chromatography-tandem mass spectrometry based method for the quantification of D-amino acids in body fluids. J Chromatogr A 1218: 7130–7136.
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM et al (2008). Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539–543.
Wen L, Lu YS, Zhu XH, Li XM, Woo RS, Chen YJ et al (2010). Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc Natl Acad Sci USA 107: 1211–1216.
Woo RS, Li XM, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J et al (2007). Neuregulin-1 enhances depolarization-induced GABA release. Neuron 54: 599–610.
Acknowledgements
We thank professor Dr JTA Knape and Dr P Vaessen for their valuable assistance in developing our CSF sampling protocol in the operating rooms.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
PowerPoint slides
Rights and permissions
About this article
Cite this article
Luykx, J., Vinkers, C., Bakker, S. et al. A Common Variant in ERBB4 Regulates GABA Concentrations in Human Cerebrospinal Fluid. Neuropsychopharmacol 37, 2088–2092 (2012). https://doi.org/10.1038/npp.2012.57
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2012.57
Keywords
This article is cited by
-
A network of transcriptomic signatures identifies novel comorbidity mechanisms between schizophrenia and somatic disorders
Discover Mental Health (2024)
-
Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease
Nature Medicine (2023)
-
Spine impairment in mice high-expressing neuregulin 1 due to LIMK1 activation
Cell Death & Disease (2021)
-
ERBB4 polymorphism and family history of psychiatric disorders on age-related cortical changes in healthy children
Brain Imaging and Behavior (2015)
-
Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma
Molecular Psychiatry (2015)
